Have a feature idea you'd love to see implemented?
Let us know!
PTCT Ptc Therapeutics Inc
Price (delayed)
$41.4
Market cap
$3.18B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.31
Enterprise value
$2.93B
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally
Highlights
The quick ratio has surged by 94% year-on-year and by 12% since the previous quarter
The company's debt fell by 44% YoY and by 6% QoQ
Ptc Therapeutics's revenue has increased by 10% YoY but it has decreased by 2.9% from the previous quarter
PTCT's gross profit is up by 8% YoY but it is down by 3.5% QoQ
Ptc Therapeutics's equity has shrunk by 69% YoY and by 10% QoQ
Key stats
What are the main financial stats of PTCT
Market
Valuations
Earnings
Shares outstanding
76.92M
Market cap
$3.18B
Enterprise value
$2.93B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.25
Revenue
$900.45M
EBIT
-$337.31M
EBITDA
-$123.51M
Free cash flow
-$101.6M
Per share
Balance sheet
Liquidity
EPS
-$6.31
Free cash flow per share
-$1.32
Book value per share
-$12.78
Revenue per share
$11.74
TBVPS
$19.6
Total assets
$1.92B
Total liabilities
$2.9B
Debt
$395.5M
Equity
-$980.18M
Working capital
$748.11M
Debt to equity
-0.4
Current ratio
2.23
Quick ratio
2.1
Net debt/EBITDA
2.1
Margins
Efficiency
Dividend
EBITDA margin
-13.7%
Gross margin
92.4%
Net margin
-53.3%
Operating margin
-21.6%
Return on assets
-28%
Return on equity
N/A
Return on invested capital
-48.8%
Return on capital employed
-25.8%
Return on sales
-37.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTCT stock price
How has the Ptc Therapeutics stock price performed over time
Intraday
-2.54%
1 week
11.86%
1 month
13.36%
1 year
78.29%
YTD
50.22%
QTD
11.59%
Financial performance
How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$900.45M
Gross profit
$831.58M
Operating income
-$194.22M
Net income
-$479.52M
Gross margin
92.4%
Net margin
-53.3%
PTCT's operating margin has surged by 75% year-on-year and by 60% since the previous quarter
The company's operating income has surged by 73% YoY and by 61% QoQ
The company's net margin rose by 29% YoY and by 15% QoQ
The net income has grown by 22% YoY and by 17% from the previous quarter
Growth
What is Ptc Therapeutics's growth rate over time
Valuation
What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.25
The EPS is up by 25% year-on-year and by 18% since the previous quarter
Ptc Therapeutics's equity has shrunk by 69% YoY and by 10% QoQ
The price to sales (P/S) is 53% higher than the last 4 quarters average of 2.3 but 38% lower than the 5-year quarterly average of 5.7
Ptc Therapeutics's revenue has increased by 10% YoY but it has decreased by 2.9% from the previous quarter
Efficiency
How efficient is Ptc Therapeutics business performance
The ROS is up by 48% year-on-year and by 31% since the previous quarter
The ROIC has grown by 31% YoY and by 28% from the previous quarter
Ptc Therapeutics's ROA has increased by 29% YoY and by 24% from the previous quarter
Dividends
What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTCT.
Financial health
How did Ptc Therapeutics financials performed over time
The total assets is 34% less than the total liabilities
The quick ratio has surged by 94% year-on-year and by 12% since the previous quarter
Ptc Therapeutics's current ratio has surged by 80% YoY and by 10% QoQ
The company's debt is 140% higher than its equity
Ptc Therapeutics's equity has shrunk by 69% YoY and by 10% QoQ
PTCT's debt to equity has surged by 67% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.